达格列净对接受托伐普坦治疗的常染色体显性多囊肾病患者影响的开放标签随机对照交叉试验
该开放标签随机对照交叉试验纳入27例接受托伐普坦治疗的常染色体显性多囊肾病(ADPKD)患者,随机接受达格列净10 mg或常规护理6个月。结果显示,达格列净组eGFRcr-cys和eGFRcys斜率显著改善,总肾脏体积(TKV)变化显著减缓,提示达格列净可能具有延缓ADPKD进展的附加效应。
要点
- 达格列净显著改善接受托伐普坦的ADPKD患者eGFRcr-cys和eGFRcys斜率。
- 达格列净组6个月TKV变化显著减缓。
- eGFRcr斜率变化呈潜在趋势但未达统计学显著性。
核心结论
- 在接受托伐普坦治疗的ADPKD患者中,达格列净可能具有延缓疾病进展的附加效应。
研究设计与样本
- 开放标签、随机、对照、交叉试验,共纳入27例接受托伐普坦治疗的ADPKD患者。
- 患者随机接受达格列净10 mg或不用达格列净的常规护理,为期6个月。
主要发现
- 达格列净组eGFRcr-cys斜率为2.57 ± 7.88 ml/min per 1.73 m2 per year,对照组为-5.65 ± 9.57 ml/min per 1.73 m2 per year,P = 0.002。
- 达格列净组eGFRcys斜率为3.91 ± 11.40 ml/min per 1.73 m2 per year,对照组为-8.43 ± 13.44 ml/min per 1.73 m2 per year,P = 0.003。
- 达格列净组eGFRcr斜率为1.03 ± 10.78 ml/min per 1.73 m2 per year,对照组为-3.66 ± 8.88 ml/min per 1.73 m2 per year,P = 0.06。
- 达格列净组6个月TKV变化为-0.44 ± 4.91%,对照组为5.04 ± 8.09%,P = 0.01。
临床怎么用
- 对于接受托伐普坦治疗的ADPKD患者,加用达格列净可能进一步延缓肾功能下降和肾脏体积增长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney disease (ADPKD) has not been established. We conducted an open-label, randomized controlled crossover trial to evaluate the additive effects of dapagliflozin in patients with ADPKD receiving tolvaptan. METHODS: A total of 27 patients were randomly counterbalanced to receive dapagliflozin 10 mg or usual care without dapagliflozin for 6 months. The primary endpoint was the slope of the estimated glomerular filtration rate (eGFR) determined by linear regression from 1 to 6 months, and the secondary endpoints included changes in total kidney volume (TKV). eGFR was calculated based on creatinine levels (eGFRcr), cystatin C levels (eGFRcys), and the mean of eGFRcr and eGFRcys (eGFRcr-cys). RESULTS: There were significant attenuations in the eGFRcr-cys and eGFRcys slopes during the dapagliflozin trial compared with the one without dapagliflozin (2.57 ± 7.88 vs. -5.65 ± 9.57 ml/min per 1.73 m2 per year, P = 0.002; 3.91 ± 11.40 vs. -8.43 ± 13.44 ml/min per 1.73 m2 per year, P = 0.003, respectively). Meanwhile, the eGFRcr slope was potentially moderate during the trial with dapagliflozin (1.03 ± 10.78 vs. -3.66 ± 8.88 ml/min per 1.73 m2 per year, P = 0.06). The 6-month change in TKV was significantly attenuated during the trial with dapagliflozin compared with the one without dapagliflozin (-0.44 ± 4.91% vs. 5.04 ± 8.09%, P = 0.01). CONCLUSION: In patients with ADPKD treated with tolvaptan, dapagliflozin may have an additive effect in slowing ADPKD progression.
引用
- Uchiyama K, Kamano D, Nagasaka T, et al. Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan. Kidney Int Rep. 2025. PMID: 40303212. doi:10.1016/j.ekir.2025.01.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。